Albert Bourla, CEO of global pharmaceutical giant Pfizer, claims the vaccine will be ready for Covid-19 prevention by the end of October.
Pfizer is conducting clinical trials in the US and Europe for the BNT 1662 vaccine program for the prevention of covid-19 in collaboration with German mRNA company BioNTech.
In a virtual event hosted by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) this week, Bourla said:
If things go well and the FDA (US Food and Drug Administration) and the EMA (European Medicines Agency) feel comfortable, the vaccine will be available by the end of October.
AstraZeneca CEO Pascal Soriot, GlaxoSmithKline (GSK) chief Emma Walmsley, and Johnson & Johnson Chief Scientific Officer Paul Stoffels were also present.
Each of these companies is working with their partners to develop a vaccine to prevent the disease.
While working with GSK Sanofi, AstraZeneca supports vaccines being developed at the University of Oxford.
Johnson and Johnson are partnering with the US Biomedical Advanced Research and Development Authority to develop the vaccine.
More than 120 vaccines are currently being developed worldwide. Currently, there are at least 10 candidate vaccines in clinical evaluation and 115 candidate vaccines in pre-clinical evaluation.
According to the World Health Organization, it is important to evaluate as many vaccines as possible, and we cannot predict how many will be effective.
To increase the likelihood of success, it is crucial to check until all candidate vaccines fail, the WHO said.
Pfizer’s and BioTech’s development program includes four vaccine candidates. Each represents a different combination of mRNA format and target antigen.